SCHEMBL4382429

SCHEMBL4382429

CCC(C)(O)C(=O)Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 19/20 0.73
JAK3 P52333 14/20 0.67
JAK1 P23458 7/20 0.67
TYK2 P29597 5/20 0.67
HDAC1 Q13547 3/20 0.64
HDAC6 Q9UBN7 2/20 0.64
HDAC3 O15379 1/20 0.64
NCOR1 O75376 1/20 0.64
HDAC2 Q92769 1/20 0.64
HDAC8 Q9BY41 1/20 0.64
PLK4 O00444 2/20 0.62
CIT O14578 2/20 0.62
GAK O14976 2/20 0.62
ROCK2 O75116 2/20 0.62
PRKD3 O94806 2/20 0.62
CSNK2A2 P19784 2/20 0.62
MARK3 P27448 2/20 0.62
MAPK8 P45983 2/20 0.62
NEK3 P51956 2/20 0.62
IKBKE Q14164 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4387595 1.00 JAK2 (0.73) JAK2JAK3JAK1TYK2HDAC1
SCHEMBL4382419 1.00 JAK2 (0.73) JAK2JAK3JAK1TYK2HDAC1
SCHEMBL4376899 0.91 JAK2 (0.78) JAK2JAK3JAK1TYK2HDAC1
SCHEMBL4376864 0.89 JAK2 (0.78) JAK2JAK3JAK1TYK2HDAC1
SCHEMBL13588470 0.88 JAK2 (0.74) JAK2JAK3JAK1TYK2HDAC1
SCHEMBL4390385 0.86 JAK2 (0.80) JAK2JAK3JAK1TYK2HDAC1
SCHEMBL4377378 0.86 JAK2 (0.53) JAK2JAK3JAK1TYK2HDAC1
SCHEMBL4377388 0.86 JAK2 (0.53) JAK2JAK3JAK1TYK2HDAC1
SCHEMBL8075563 0.85 JAK2 (0.75) JAK2JAK3JAK1TYK2HDAC1
SCHEMBL4390308 0.85 JAK2 (1.00) JAK2JAK3JAK1TYK2HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8440663-B2 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2013-05-14 US disclosed
US-20090298830-A1 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2009-12-03 US disclosed
WO-2009017838-A2 COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS EXELIXIS, INC. (US) 2009-02-05 WO disclosed
WO-2008124085-A2 METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS EXELIXIS, INC. (US) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298830-A1 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use JAK2, JAK1, JAK3 JAK2 1/4885JAK3 3/4885JAK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.